NGEN NASDAQ
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
West Vancouver, BC V6Z 2R4
CA
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Dreismann Heiner | A-Award | 59,524 | — | 2008-06-25 |
| SCHREIBER DAVID | A-Award | 59,524 | — | 2008-06-25 |
| BIRNDORF HOWARD C | A-Award | 547,500 | $0.42 | 2008-04-02 |
| Dreismann Heiner | A-Award | 18,116 | — | 2007-06-13 |
| SCHREIBER DAVID | A-Award | 18,116 | — | 2007-06-13 |